|Development and Manufacturing|
Our API business is supported by technologically advanced API research and development infrastructure, which develops new products and is engaged upto the delivery of products to the market.
The API research division is housed in a sprawling 15-acre campus with a built up area of over five hundred thousand square feet which houses both chemical and analytical research along with a kilo lab. With experience of commercializing over 200 APIs, the research team is completely attuned to our growth aspirations. Committed to quality, safety and the environment, five of our manufacturing facilities have been inspected and approved by the US FDA, UK MHRA, TGA Australia, ANVISA and other reputed regulatory agencies.
Our state-of-the-art manufacturing plants ensure that we deliver quality and scale. We have successfully integrated our capabilities and capacities to deliver a wide product portfolio that caters to the needs of diverse markets. Aurobindo operates dedicated facilities for categories from intermediates to oral and sterile betalactams. There are multiple site filings to mitigate the supply risk and to ensure business continuity. Aurobindo API plants are equipped with particle size modifications systems to supply compacted and micronized materials.
Manufacturing is backed by warehousing systems that offer ambient control room temperature (CRT) and cold rooms. API plants are equipped by site dedicated quality control laboratories. We practice DIMAP, FEMA methodologies as part of our QMS.
We offer the complete bandwidth of products in Penicillins, Cephalosporins, Anti-retroviral, Anti-infectives and other non betalactams. We also offer sterile and non sterile anti-biotics.
Aurobindo has evolved into a knowledge driven...Strategic Alliance
Our Corporate Social Responsibility includes...Social Responsibility
Aurobindo Pharma has a team of more than...Global Family
Financial Results of Aurobindo Pharma...Investor Relations